Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

ClinicalTrials.gov ID: NCT02114151

Public ClinicalTrials.gov record NCT02114151. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis

Study identification

NCT ID
NCT02114151
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Enrollment
103 participants

Conditions and interventions

Interventions

  • Simeprevir Drug
  • Sofosbuvir Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2014
Primary completion
Dec 31, 2014
Completion
Mar 31, 2015
Last update posted
Apr 3, 2016

2014 – 2015

United States locations

U.S. sites
32
U.S. states
15
U.S. cities
32
Facility City State ZIP Site status
Not listed Dothan Alabama
Not listed Bakersfield California
Not listed Chula Vista California
Not listed Los Angeles California
Not listed San Diego California
Not listed Englewood Colorado
Not listed Bradenton Florida
Not listed Lauderdale Lakes Florida
Not listed Maitland Florida
Not listed Miami Florida
Not listed Orlando Florida
Not listed Wellington Florida
Not listed Atlanta Georgia
Not listed Columbus Georgia
Not listed Marietta Georgia
Not listed Jackson Mississippi
Not listed Kansas City Missouri
Not listed Hillsborough New Jersey
Not listed Vineland New Jersey
Not listed New York New York
Not listed Asheville North Carolina
Not listed Winston-Salem North Carolina
Not listed East Greenwich Rhode Island
Not listed Providence Rhode Island
Not listed Greer South Carolina
Not listed Germantown Tennessee
Not listed Knoxville Tennessee
Not listed Nashville Tennessee
Not listed Arlington Texas
Not listed Austin Texas
Not listed San Antonio Texas
Not listed Norfolk Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02114151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2016 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02114151 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →